Currently, Pembrolizumab, FAZ053, PDR001, and Atezolizumab (α-PD-1 mAbs) are also being assessed as a potential for CH treatment as either monotherapy or combination therapy [18,19,26]. The gene discussed is PDCD1; the disease is cyclic hematopoiesis.